Peripheral T-Cell Lymphoma, Not Otherwise Specified

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DIS-PTCL-NOS`
Type	Disease
Aliases	PTCL NOSPTCL-UPeripheral T-Cell Lymphoma, NOSПериферична T-клітинна лімфома, неуточнена
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology	9702/3
icd_10	C84.4
who_classification	Mature T-cell neoplasms — Peripheral T-cell lymphoma, NOS per WHO 5th ed.

Capabilities

Notes

Diagnosis-of-exclusion — once specific T-cell entities (AITL, ALCL, EATL, NK/T, hepatosplenic, cutaneous) ruled out. CD30 expression in ~40-60% — qualifies for brentuximab-CHP per ECHELON-2.

Used By

Algorithms

ALGO-PTCL-1L - ALGO-PTCL-1L
ALGO-PTCL-2L - ALGO-PTCL-2L

Disease

DIS-AITL - Angioimmunoblastic T-Cell Lymphoma / Nodal TFH-cell lymphoma
DIS-ALCL - Anaplastic Large Cell Lymphoma (systemic)
DIS-ATLL - Adult T-Cell Leukemia/Lymphoma
DIS-EATL - Enteropathy-Associated T-Cell Lymphoma
DIS-HSTCL - Hepatosplenic T-Cell Lymphoma
DIS-MF-SEZARY - Mycosis Fungoides / Sézary Syndrome
DIS-NK-T-NASAL - Extranodal NK/T-Cell Lymphoma, Nasal Type
DIS-T-ALL - T-Lymphoblastic Leukemia / Lymphoma
DIS-T-PLL - T-Cell Prolymphocytic Leukemia

Indication

IND-PTCL-1L-CHOEP-ALLOSCT - IND-PTCL-1L-CHOEP-ALLOSCT
IND-PTCL-2L-PRALATREXATE - IND-PTCL-2L-PRALATREXATE
IND-PTCL-2L-ROMIDEPSIN - IND-PTCL-2L-ROMIDEPSIN
IND-TCELL-1L-CHOEP - IND-TCELL-1L-CHOEP

Questionnaires

QUEST-PTCL-NOS-1L-STUB - Peripheral T-Cell Lymphoma, NOS — first line

Red flag

RF-PTCL-NOS-FRAILTY-AGE - Frailty profile precluding full-dose CHOEP / CHP-Bv induction in PTCL NOS: ECOG ≥3, OR (a...
RF-PTCL-NOS-INFECTION-SCREENING - Active or latent infection requiring resolution / prophylaxis before initiating CHOEP / C...
RF-PTCL-NOS-ORGAN-DYSFUNCTION - Baseline organ dysfunction precluding standard CHOEP / CHP-Bv induction in PTCL NOS: LVEF...
RF-PTCL-NOS-TRANSFORMATION-PROGRESSION - PTCL NOS primary-refractory disease (no CR after induction) OR early relapse <12 months p...
RF-TCELL-CD30-POSITIVE - Reported CD30 expression in T-cell lymphoma; a targeting signal requiring confirmed patho...

Sources

SRC-ESMO-LYMPHOMA-2025 - Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
SRC-ESMO-PTCL-2024 - ESMO Clinical Practice Guideline on Peripheral T-cell Lymphomas